KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Current Assets (2020 - 2025)

Historic Current Assets for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to $695.1 million.

  • AbCellera Biologics' Current Assets fell 642.67% to $695.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $695.1 million, marking a year-over-year decrease of 642.67%. This contributed to the annual value of $751.4 million for FY2024, which is 1383.22% down from last year.
  • According to the latest figures from Q3 2025, AbCellera Biologics' Current Assets is $695.1 million, which was down 642.67% from $742.1 million recorded in Q2 2025.
  • AbCellera Biologics' 5-year Current Assets high stood at $1.2 billion for Q1 2022, and its period low was $695.1 million during Q3 2025.
  • Its 5-year average for Current Assets is $886.3 million, with a median of $872.0 million in 2023.
  • In the last 5 years, AbCellera Biologics' Current Assets soared by 3240.19% in 2022 and then crashed by 1990.2% in 2023.
  • Over the past 5 years, AbCellera Biologics' Current Assets (Quarter) stood at $929.8 million in 2021, then grew by 10.29% to $1.0 billion in 2022, then dropped by 14.97% to $872.0 million in 2023, then decreased by 13.83% to $751.4 million in 2024, then decreased by 7.48% to $695.1 million in 2025.
  • Its last three reported values are $695.1 million in Q3 2025, $742.1 million for Q2 2025, and $765.0 million during Q1 2025.